69 related articles for article (PubMed ID: 9717833)
41. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.
Disis ML; Calenoff E; McLaughlin G; Murphy AE; Chen W; Groner B; Jeschke M; Lydon N; McGlynn E; Livingston RB
Cancer Res; 1994 Jan; 54(1):16-20. PubMed ID: 7505195
[TBL] [Abstract][Full Text] [Related]
42. [The effect of new synthetic fragments of thymus hormones on the proliferative response of lymphocytes].
Ivanova VP; Sorochinskaia EI; Lozhkina TK
Vopr Med Khim; 1993; 39(3):45-7. PubMed ID: 8333191
[TBL] [Abstract][Full Text] [Related]
43. Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides.
Anderson BW; Kudelka AP; Honda T; Pollack MS; Gershenson DM; Gillogly MA; Murray JL; Ioannides CG
Cancer Immunol Immunother; 2000 Nov; 49(9):459-68. PubMed ID: 11092612
[TBL] [Abstract][Full Text] [Related]
44. Detection of Primary T Cell Responses to Drugs and Chemicals in HLA-Typed Volunteers: Implications for the Prediction of Drug Immunogenicity.
Faulkner L; Gibson A; Sullivan A; Tailor A; Usui T; Alfirevic A; Pirmohamed M; Naisbitt DJ; Kevin Park B
Toxicol Sci; 2016 Dec; 154(2):416-429. PubMed ID: 27637899
[TBL] [Abstract][Full Text] [Related]
45. Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients.
Bailur JK; Derhovanessian E; Gueckel B; Pawelec G
J Immunother Cancer; 2015; 3():45. PubMed ID: 26500775
[TBL] [Abstract][Full Text] [Related]
46. Does HER-2/neu antigen loss in metastatic breast tumors occur under immune pressure?
Manjili MH; Kmieciak M
Int J Cancer; 2008 Sep; 123(6):1476-7; author reply 1478-9. PubMed ID: 18566999
[No Abstract] [Full Text] [Related]
47. Extraction of tissue antigens for functional assays.
Necula A; Chand R; Albatat B; Mannering SI
J Vis Exp; 2012 Sep; (67):. PubMed ID: 22986305
[TBL] [Abstract][Full Text] [Related]
48. Advancements in Human Breast Cancer Targeted Therapy and Immunotherapy.
Bou-Dargham MJ; Draughon S; Cantrell V; Khamis ZI; Sang QA
J Cancer; 2021; 12(23):6949-6963. PubMed ID: 34729098
[TBL] [Abstract][Full Text] [Related]
49. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.
Mittendorf EA; Ardavanis A; Symanowski J; Murray JL; Shumway NM; Litton JK; Hale DF; Perez SA; Anastasopoulou EA; Pistamaltzian NF; Ponniah S; Baxevanis CN; von Hofe E; Papamichail M; Peoples GE
Ann Oncol; 2016 Jul; 27(7):1241-8. PubMed ID: 27029708
[TBL] [Abstract][Full Text] [Related]
50. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.
Kaumaya PT; Foy KC
Future Oncol; 2012 Aug; 8(8):961-87. PubMed ID: 22894670
[TBL] [Abstract][Full Text] [Related]
51. HLA-DR: molecular insights and vaccine design.
Stern LJ; Calvo-Calle JM
Curr Pharm Des; 2009; 15(28):3249-61. PubMed ID: 19860674
[TBL] [Abstract][Full Text] [Related]
52. In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines.
Singh R; Paterson Y
Cancer Immunol Immunother; 2007 Jun; 56(6):927-38. PubMed ID: 17131121
[TBL] [Abstract][Full Text] [Related]
53. Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors.
Sotiriadou NN; Kallinteris NL; Gritzapis AD; Voutsas IF; Papamichail M; von Hofe E; Humphreys RE; Pavlis T; Perez SA; Baxevanis CN
Cancer Immunol Immunother; 2007 May; 56(5):601-13. PubMed ID: 16960693
[TBL] [Abstract][Full Text] [Related]
54. Immunogenic HER-2/neu peptides as tumor vaccines.
Baxevanis CN; Sotiriadou NN; Gritzapis AD; Sotiropoulou PA; Perez SA; Cacoullos NT; Papamichail M
Cancer Immunol Immunother; 2006 Jan; 55(1):85-95. PubMed ID: 15948002
[TBL] [Abstract][Full Text] [Related]
55. IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion.
Knutson KL; Disis ML
Clin Exp Immunol; 2004 Feb; 135(2):322-9. PubMed ID: 14738463
[TBL] [Abstract][Full Text] [Related]
56. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope.
Sotiriadou R; Perez SA; Gritzapis AD; Sotiropoulou PA; Echner H; Heinzel S; Mamalaki A; Pawelec G; Voelter W; Baxevanis CN; Papamichail M
Br J Cancer; 2001 Nov; 85(10):1527-34. PubMed ID: 11720440
[TBL] [Abstract][Full Text] [Related]
57. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients.
Tuttle TM; Anderson BW; Thompson WE; Lee JE; Sahin A; Smith TL; Grabstein KH; Wharton JT; Ioannides CG; Murray JL
Clin Cancer Res; 1998 Aug; 4(8):2015-24. PubMed ID: 9717833
[TBL] [Abstract][Full Text] [Related]
58. HER-2 peptides p776 and F7, N-terminal-linked with Ii-Key tetramer (LRMK) help the proliferation of E75-TCR+ cells: The dependency of help on the side chains of LRMK-extended peptide pointed towards the T cell receptor.
Li Y; Ishiyama S; Matsueda S; Tsuda N; Ioannides CG
Oncol Rep; 2008 Jun; 19(6):1445-52. PubMed ID: 18497949
[TBL] [Abstract][Full Text] [Related]
59. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes.
Ko BK; Efferson CL; Kawano K; Kuerer HM; Sahin A; Murray JL; Ioannides CG
Int J Oncol; 2004 Jun; 24(6):1413-8. PubMed ID: 15138582
[TBL] [Abstract][Full Text] [Related]
60. Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides.
Fisk B; Hudson JM; Kavanagh J; Wharton JT; Murray JL; Ioannides CG; Kudelka AP
Anticancer Res; 1997; 17(1A):45-53. PubMed ID: 9066629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
